'Modified' Common Antibiotic May Beat Risk of Hearing Loss

by Vishnuprasad on January 5, 2015 at 9:19 PM
'Modified' Common Antibiotic May Beat Risk of Hearing Loss

Scientists have developed a modified version of an aminoglycoside, the most commonly used class of antibiotics worldwide, that may eliminate the risk of hearing loss.

Treatment with aminoglycosides is often a lifesaving necessity. However, an estimated 20-60% of all patients who receive these antibiotics suffer partial or complete hearing loss.


Researchers at the Stanford University School of Medicine have conducted a study where the new version of antibiotic worked effectively in mice without the risk of causing deafness.

It took the scientists 4 years of research to produce 5 grams of the newly patented antibiotic, N1MS, which is derived from sisomicin, a type of aminoglycoside.

The study presents a promising new approach to generating a new class of novel, nontoxic antibiotics.

Because aminoglycosides cause deafness by killing these nonregenerating hair cells, Anthony Ricci, PhD, postulated, why not simply make the drug molecules unable to enter the cells' channels.

"The goal was to keep the antibacterial properties of the drug intact while preventing it from entering the inner-ear cell's ion channels," Ricci said. He and his fellow researchers used data from structural biologists at Stanford who better understood how the antibiotics fought off infection.

Ricci targeted sites on the drug molecule that were not involved in the antimicrobial activity that killed off infection. This allowed them to reduce toxicity to the ear while retaining antimicrobial action.

The study was published online in the Journal of Clinical Investigation.

Source: Medindia
Font : A-A+



Recommended Readings

Latest Drug News

Anti-Obesity Drugs' Impact on Osteoarthritis Survival
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

'Modified' Common Antibiotic May Beat Risk of Hearing Loss Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests